The drug product candidate is protected by two issued US and additional pending international patents. These patents run through 2035. In addition, Boulder BioScience has recently filed two methods of use patents describing new methods of treatment and API mechanistic activity. The recently filed patents will run through 2040. The recent patent applications claim highly relevant API activity for potential treatment of Covid 19 infection. Dr. Zeligs and co-inventor, Dr. Irwin Jacobs have worked together for over 20 years initiating the clinical evaluation of the API. This collaboration has resulted in multiple generations of patented formulation technology for the current API and for similar, poorly soluble APIs, which increase bioavailability and enable therapeutic uses.